Form 4: Nantahala Capital Management Reports Beneficial Ownership Changes in Aytu BioPharma

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported changes in their beneficial ownership of Aytu BioPharma, Inc. securities, including warrants exercisable for common stock.

Summary

• Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, filed a Form 4 with the SEC regarding changes in beneficial ownership of Aytu BioPharma, Inc. (AYTU) securities on June 14, 2024.
• The filing details the acquisition of Tranche B Warrants and Exchange Warrants.
• Nantahala Capital Management acquired 815,217 Tranche B Warrants exercisable at $1.5899 per share (or per Exchange Warrant) and 815,217 Exchange Warrants exercisable at $0.0001 per share.
• The Tranche B Warrants expire five years after issuance or 30 days after Aytu BioPharma achieves $12 million in consolidated trailing twelve-month adjusted EBITDA.
• The Exchange Warrants do not expire until fully exercised.
• Nantahala Capital Management, as an investment advisor, may be deemed a beneficial owner of the securities, but disclaims beneficial ownership except to the extent of their pecuniary interests.
• Wilmot B. Harkey and Daniel Mack may also be deemed beneficial owners of the securities held by Nantahala Capital Management and also disclaim beneficial ownership except to the extent of their pecuniary interests.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The acquisition of warrants could be seen as a positive sign of investment in the company, but it's primarily a factual disclosure.

Risks

• The value of the warrants is dependent on Aytu BioPharma's stock price and its ability to achieve certain financial milestones, such as $12 million in trailing twelve-month adjusted EBITDA.
• The expiration of the Tranche B Warrants could impact their value if Aytu BioPharma does not meet the EBITDA target within five years.

Future Outlook

The value of the warrants is tied to the future performance of Aytu BioPharma, including its ability to achieve the EBITDA target. The Exchange Warrants provide a long-term option to purchase shares at a nominal price.

Management Comments

• Nantahala Capital Management, Wilmot B. Harkey, and Daniel Mack disclaim beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

Industry Context

Form 4 filings are standard disclosures required by the SEC when there are changes in beneficial ownership of a company's securities by insiders or significant shareholders. This filing provides transparency to the market regarding the holdings and transactions of Nantahala Capital Management in Aytu BioPharma.

Comparison to Industry Standards

• Warrant structures are common in the biopharmaceutical industry, often used as incentives for investors.
• The exercise prices and expiration terms of the warrants are typical for similar financing arrangements in the sector.
• The EBITDA target for warrant expiration is a performance-based metric that aligns the interests of the warrant holders with the company's financial success.

Stakeholder Impact

• Shareholders: The filing provides information about the ownership structure of the company.
• Employees: The EBITDA target could impact employee incentives and company strategy.
• Creditors: The financial performance of the company, as reflected in the EBITDA target, could impact its creditworthiness.

Key Dates

Keywords

Aytu BioPharma, Nantahala Capital Management, Beneficial Ownership, Form 4, Warrants, Exchange Warrants, Tranche B Warrants, SEC Filing